# Patent Watch: Akos Targets Smarter Cannabinoid Del

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/patent-watch-patent-watch-akos-targets-smarter-cannabinoid-2026-10-07/
> **Published:** 2026-10-07T12:53:34-04:00 | **Last Modified / Clinically Audited:** 2026-10-07T12:53:34-04:00
> **Clinical Summary:** The application concerns cannabinoid molecules chemically linked to another molecular component, potentially creating prodrugs or targeted delivery constru

---

PATENT WATCH
 US20260191967A1
 
 

# Patent Watch: Akos Targets Smarter Cannabinoid Delivery With Conjugates

 
 **Assignee:** Akos Biosciences, Inc
 **Inventors:** Paul M. Hershberger, Yinghui Liu, Kirk William Hering, James Bernard Kramer
 **Published:** 2026-07-09
 
 

 
 Invention Summary & Claims
 

The application concerns cannabinoid molecules chemically linked to another molecular component, potentially creating prodrugs or targeted delivery constructs rather than conventional cannabinoid mixtures. These conjugate partners function as molecular modifiers or carriers, not merely inactive excipients, and may alter solubility, stability, tissue distribution, or release of the cannabinoid API.

 

 

## Clinical Perspective & Therapeutic Significance

 

A successful conjugate strategy could improve cannabinoid bioavailability, reduce variable absorption, or direct exposure toward selected tissues while limiting systemic effects. These potential advantages require pharmacokinetic, toxicology, and controlled clinical studies, since the patent filing does not establish therapeutic efficacy or improved safety.

 

## Intellectual Property & Market Landscape

 

Akos Biosciences appears to be positioning proprietary cannabinoid chemistry as a pharmaceutical development platform rather than competing directly with standard oils, capsules, flower, or edibles. Composition-of-matter claims covering conjugated molecules can offer stronger commercial differentiation than conventional formulations, although value depends on patent scope, manufacturability, regulatory progress, and clinical performance.

 
 **Official Source Document:** Review the primary patent disclosure and full claims on [Google Patents (US20260191967A1)](https://patents.google.com/patent/US20260191967A1/en).
 

 
 Editorial Commentary
 

The application reflects a credible shift from consumer-style cannabis formulations toward engineered cannabinoid medicines. Its practical significance will depend on whether the conjugates produce measurable delivery or safety advantages in human studies.

 

 
 

### Frequently Asked Questions

 
 Could cannabinoid conjugates work better than standard oral cannabinoids?
 They may improve absorption, stability, tissue targeting, or controlled release, but those benefits cannot be assumed from patent claims alone. Comparative pharmacokinetic and clinical data would be needed.

 Does this patent application mean the conjugates have completed clinical trials?
 No. A published patent application protects claimed intellectual property and does not demonstrate regulatory approval, completed clinical testing, or proven patient benefit.

 When could these cannabinoid conjugates become available to patients?
 No reliable timeline can be established from the application. Availability would require compound selection, manufacturing development, preclinical testing, clinical trials, and applicable regulatory authorization.

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).